Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II
- PMID: 9740601
- DOI: 10.1161/01.hyp.32.3.393
Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II
Abstract
The angiotensinogen gene has been linked to essential hypertension and increased blood pressure. A functional variant believed to be responsible for hypertension susceptibility occurs at position -6 in the promoter region of the gene in which an A for G base pair substitution is associated with higher angiotensinogen levels. To test whether an allele within the angiotensinogen gene is related to subsequent incidence of hypertension and blood pressure response to sustained sodium reduction, 1509 white male and female subjects participating in phase II of the Trials of Hypertension Prevention were genotyped at the angiotensinogen locus. Participants had diastolic blood pressures between 83 and 89 mm Hg and were randomized in a 2x2 factorial design to sodium reduction, weight loss, combined intervention, or usual care groups. Persons in the usual care group with the AA genotype at nucleotide position -6 had a higher 3-year incidence rate of hypertension (44.6%) compared with those with the GG genotype (31.5%), with a relative risk of 1.4 (95% confidence interval [0.87, 2.34], test for trend across all 3 genotypes, P=0.10). In contrast, the incidence of hypertension was significantly lower after sodium reduction for persons with the AA genotype (relative risk=0.57 [0.34, 0.98] versus usual care) but not for persons with the GG genotype (relative risk=1.2 [0.79, 1.81], test for trend P=0.02). Decreases of diastolic blood pressure at 36 months in the sodium reduction group versus usual care showed a significant trend across all 3 genotypes (P=0.01), with greater net blood pressure reduction in those with the AA genotype (-2.2 mm Hg) than those with the GG genotype (+1.1 mm Hg). A similar trend across the 3 genotypes for net systolic blood pressure reduction (-2.7 for AA versus -0.2 mm Hg for GG) was not significant (P=0.17). Trends across genotypes for the effects of weight loss on hypertension incidence and decreases in blood pressure were similar to those for sodium reduction. We conclude that the angiotensinogen genotype may affect blood pressure response to sodium or weight reduction and the development of hypertension.
Comment in
-
Angiotensinogen genotype and blood pressure responses to reduced dietary NaCl and to weight loss.Hypertension. 1998 Sep;32(3):402-3. doi: 10.1161/01.hyp.32.3.402. Hypertension. 1998. PMID: 9740602 No abstract available.
Similar articles
-
Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group.Arch Intern Med. 1997 Mar 24;157(6):657-67. Arch Intern Med. 1997. PMID: 9080920 Clinical Trial.
-
Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene.Am J Hypertens. 1999 May;12(5):460-6. doi: 10.1016/s0895-7061(99)00014-x. Am J Hypertens. 1999. PMID: 10342783 Clinical Trial.
-
Angiotensinogen genotype and blood pressure responses to reduced dietary NaCl and to weight loss.Hypertension. 1998 Sep;32(3):402-3. doi: 10.1161/01.hyp.32.3.402. Hypertension. 1998. PMID: 9740602 No abstract available.
-
Randomized clinical trials of weight reduction in nonhypertensive persons.Ann Epidemiol. 1991 May;1(4):363-70. doi: 10.1016/1047-2797(91)90046-f. Ann Epidemiol. 1991. PMID: 1669517 Review.
-
Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension.Pathol Biol (Paris). 1997 Mar;45(3):229-39. Pathol Biol (Paris). 1997. PMID: 9296068 Review.
Cited by
-
Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.Drugs. 2004;64(16):1801-16. doi: 10.2165/00003495-200464160-00006. Drugs. 2004. PMID: 15301563 Review.
-
Self-monitoring urinary salt excretion device can be used for controlling hypertension for developing countries.Clin Hypertens. 2019 Mar 15;25:3. doi: 10.1186/s40885-019-0109-9. eCollection 2019. Clin Hypertens. 2019. PMID: 30923632 Free PMC article. Review.
-
Reduced dietary salt for the prevention of cardiovascular disease.Cochrane Database Syst Rev. 2011 Jul 6;(7):CD009217. doi: 10.1002/14651858.CD009217. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2013 Sep 12;(9):CD009217. doi: 10.1002/14651858.CD009217.pub2. PMID: 21735439 Free PMC article. Updated.
-
Current genetics of essential hypertension.Curr Hypertens Rep. 2001 Feb;3(1):1-2. doi: 10.1007/s11906-001-0069-8. Curr Hypertens Rep. 2001. PMID: 11177700 Review. No abstract available.
-
Let us return to a more natural lifestyle.Curr Hypertens Rep. 1999 Oct;1(5):363-4. doi: 10.1007/s11906-999-0047-0. Curr Hypertens Rep. 1999. PMID: 10981091 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical